IP Library › Granted Patent US 7,615,530
Granted Patent B2
US 7,615,530 · App. 11/586,340 · Granted Nov 10, 2009

Immunogenic compositions and methods of use

Assignee: Artificial Cell Technologies, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,615,530
App. No.
11/586,340
Granted
Nov 10, 2009
Kind
B2
Abstract

Disclosed herein are immunogenic compositions comprising a multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polyelectrolyte comprises an antigenic polypeptide comprising one or more surface adsorption regions covalently linked to one or more antigenic determinant regions, wherein the antigenic polypeptide and the one or more surface adsorption regions have the same polarity. The immunogenic compositions may be employed in methods of eliciting an immune response in a vertebrate organism.

Claims (39)

1. A multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes,

wherein a first layer polyelectrolyte comprises a first antigenic polypeptide comprising one or more surface adsorption regions covalently linked to one or more antigenic determinant regions, wherein the first antigenic polypeptide and the one or more surface adsorption regions have the same polarity,

wherein the one or more surface adsorption regions comprises one or more amino acid sequence motifs, the one or more amino acid sequence motifs consisting of 5 to 15 amino acid residues and having a magnitude of net charge per residue of greater than or equal to 0.4, and

wherein the one or more antigenic determinant regions comprises 3 to about 250 amino acid residues, and one or more antigenic determinant regions comprises a viral antigen,

wherein the first antigenic polypeptide is an unbranched polypeptide, is not a homopolymer, is at least 15 amino acid residues long, and has an aqueous solubility at pH 4 to 10 of greater than 50 μg/ml;

wherein a second layer comprises a second layer polyelectrolyte comprising a polycationic material or a polyanionic material having a molecular weight of greater than 1,000 and at least 5 charges per molecule, and a charge opposite that of the first layer polypeptide.

2. The multilayer film of claim 1 , wherein the first antigenic polypeptide is in the exterior layer of the multilayer film.

3. The multilayer film of claim 1 , wherein the first antigenic polypeptide comprises two or more antigenic determinants.

4. The multilayer film of claim 3 , wherein the two or more antigenic determinants are from the same or different pathogen or target disease.

5. The multilayer film of claim 1 , further comprising a second antigenic polypeptide comprising one or more second surface adsorption regions covalently linked to one or more second antigenic determinant regions, wherein the second antigenic polypeptide and the one or more second surface adsorption regions have the same polarity,

wherein the one or more second surface adsorption regions comprises one or more second amino acid sequence motifs, the one or more second amino acid sequence motifs consisting of 5 to 15 amino acids and having a magnitude of net charge per residue of greater than or equal to 0.4, and

wherein the one or more second antigenic determinant regions comprises 3 to about 250 amino acid residues,

wherein the second antigenic polypeptide is not a homopolymer, is at least 15 amino acids long, and has an aqueous solubility at pH 4 to 10 of greater than 50 μg/ml.

6. The multilayer film of claim 5 , wherein the one or more first antigenic determinant regions and the one or more second antigenic determinant regions are from the same or different virus.

7. The multilayer film of claim 1 , further comprising a drug, an oligonucleotide, a nucleic acid, a lipid, a phospholipid, a carbohydrate, a polysaccharide, a lipopolysaccharide, or a combination of one or more of the foregoing molecules.

8. The multilayer film of claim 1 , wherein the antigenic polypeptide has an aqueous solubility of greater than or equal to about 1 mg/mL.

9. The multilayer film of claim 1 , wherein the one or more antigenic determinant regions comprises an antigenic motif comprising 3 to about 50 amino acid residues, and wherein the first antigenic polypeptide has a magnitude of charge per residue at neutral pH of greater than or equal to 0.4.

10. The multilayer film of claim 1 , wherein the one or more antigenic determinant regions is an antigenic domain comprising about 50 to about 250 amino acid residues.

11. The multilayer film of claim 10 , wherein the antigenic domain has a water solubility at pH 4 to 10 of greater than 50 μg/mL.

12. The multilayer film of claim 1 , wherein the multilayer film encapsulates one or more non-peptide molecules.

13. The multilayer film of claim 1 , wherein the multilayer film is in the form of a microcapsule.

14. The multilayer film of claim 13 , wherein the microcapsule comprises a core comprising a drug, a protein, an oligonucleotide, a nucleic acid, a lipid, a phospholipid, a carbohydrate, a polysaccharide, a lipopolysaccharide, or a combination of one or more of the foregoing molecules.

15. A method of eliciting an immune response in a vertebrate organism comprising administering into the vertebrate organism composition comprising,

a multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes,

wherein a first layer polyelectrolyte comprises a first antigenic polypeptide comprising one or more surface adsorption regions covalently linked to one or more antigenic determinant regions, wherein the antigenic polypeptide and the one or more surface adsorption regions have the same polarity,

wherein the one or more surface adsorption regions comprises one or more amino acid sequence motifs, the one or more amino acid sequence motifs consisting of 5 to 15 amino acids and having a magnitude of net charge per residue of greater than or equal to 0.4, and

wherein the one or more antigenic determinant regions comprises 3 to about 250 amino acid residues, and one or more antigenic determinant regions comprises a viral antigen,

wherein the antigenic polypeptide is an unbranched polypeptide, is not a homopolymer, is at least 15 amino acid residues long, and has an aqueous solubility at pH 4 to 10 of greater than 50 μg/ml;

wherein a second layer comprises a second layer polyelectrolyte comprising a polycationic material or a polyanionic material having a molecular weight of greater than 1,000 and at least 5 charges per molecule, and a charge opposite that of the first layer polypeptide.

16. The method of claim 15 , wherein the multilayer film is administered intramuscularly or subcutaneously.

17. A method of making a multilayer film, the method comprising:

depositing a first layer polyelectrolyte on a surface of a substrate to form a first layer; wherein, the first layer polyelectrolyte comprises a first antigenic polypeptide comprising one or more surface adsorption regions covalently linked to one or more antigenic determinant regions, wherein the first antigenic polypeptide and the one or more surface adsorption regions have the same polarity,

wherein the one or more surface adsorption regions comprises one or more amino acid sequence motifs, the one or more amino acid sequence motifs consisting of 5 to 15 amino acids and having a magnitude of net charge per residue of greater than or equal to 0.4, and

wherein the one or more antigenic determinant regions comprises 3 to about 250 amino acid residues, and one or more antigenic determinant regions comprises a viral antigen,

wherein the first antigenic polypeptide is an unbranched polypeptide, is not a homopolymer, is at least 15 amino acid residues long, and has an aqueous solubility at pH 4 to 10 of greater than 50 μg/ml;

depositing a second layer polyelectrolyte on the first layer polyelectrolyte to form a second layer; wherein a second layer comprises a second layer polyelectrolyte comprising a polycationic material or a polyanionic material having a molecular weight of greater than 1,000 and at least 5 charges per molecule, and a charge opposite that of the first layer polypeptide.

18. The multilayer film of claim 1 , wherein the first antigenic polypeptide is an unbranched polypeptide.

19. The multilayer film of claim 1 , wherein the one or more surface adsorption regions is non-homopolymeric.

20. The multilayer film of claim 1 , wherein the viral antigen is selected from the group consisting of an HIV-1 antigen: a hepatitis A, B or C antigen; an influenza virus antigen; a measles viral antigen; a rubella virus antigen; a rotavirus antigen; a cytomegalovirus antigen; a respiratory syncytial viral antigen; a herpes simplex viral antigen; a varicella zoster virus antigen; a Japanese encephalitis virus antigen; and a rabies virus antigen.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2025
From: ARTIFICIAL CELL TECHNOLOGIES INC
To: TARGETED NANO TECHNOLOGIES LLC
Reel/Frame 072557/0695 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CHANGE THE ASSIGNMENT DOCUMENT ITSELF: NEW ASM AND INCORRECT ASM ATTACHED PREVIOUSLY RECORDED ON REEL 020998 FRAME 0818. ASSIGNOR(S) HEREBY CONFIRMS THE REPLACEMENT ASSIGNMENT. Recorded Sep 16, 2008
From: HAYNIE, DONALD T.
To: ARTIFICIAL CELL TECHNOLOGIES, INC.
Reel/Frame 021533/0213 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2008
From: HAYNIE, DONALD T.
To: ARTIFICIAL CELL TECHNOLOGIES, INC.
Reel/Frame 020998/0818 →
Continuity (2)
Provisional Application 6072982800 · Oct 25, 2005
Related Publication 20070077253A1 · Apr 5, 2007